Brought to you by 
FOPO nets $94mm for Cadence Pharmaceuticals
28 Mar 2011
Executive Summary
Cadence Pharmaceuticals Inc. (drugs for hospitalized patients) has netted $94mm through the follow-on public offering of 12.5mm common shares at $8 each (including the overallotment). The company will use some of the proceeds to market Ofirmev, which was approved this month for mild-to-severe pain in people who cannot take oral medications.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com